On November 6, 2019, LQT Therapeutics Inc. (LQTT) closed the first tranche of its $1.8 million seed round led by Fonds de solidarité des travailleurs du Québec (F.T.Q.). The funding will be used to accelerate research of new therapies for Long QT Syndrome (LQTS) and other cardia arrhythmias as well as allow LQTT to continue advancing pre-clinical development to a series of novel compounds. The funding will also enable LQTT to explore a class of molecules and licensed intellectual property targeting a unique pathway for treatment of LQTS and other cardiovascular arrythmias.
LQT Therapeutics Inc. is a biopharmaceutical company specialized in discovering and developing therapies for the treatment of all forms of Long QT Syndrome.
Fonds de solidarité des travailleurs du Québec (F.T.Q.) is a Québec based development capital fund.
Osler, Hoskin & Harcourt LLP advised LQT Therapeutics Inc. with a team consisting of Nathalie Beauregard and Aidan McNeil (Corporate).